H.B. Fuller Company (NYSE: FUL) has recently announced the appointment of Celine Martin to its Board of Directors, effective December 1, 2025. Ms. Martin brings over 30 years of experience in the global MedTech industry, with expertise across surgical, cardiology, endovascular, and neurovascular segments.
As the largest pureplay adhesives manufacturer in the world, H.B. Fuller continues to focus on innovation and expansion in high-margin markets like medical. This strategic focus is reinforced by the company's transformation journey toward achieving a greater than 20% EBITDA margin.
Ms. Martin's appointment supports H.B. Fuller's commitment to bold leadership and strategic focus in high-growth markets like medical. Her deep expertise in the global MedTech industry and collaborative work with the medical community align seamlessly with H.B. Fuller’s customer-centric approach to innovation.
With this appointment, H.B. Fuller further strengthens its governance and strategic capabilities to support long-term value creation for shareholders, customers, and employees.
H.B. Fuller, founded in 1887, reported a revenue of $3.6 billion in 2024 and operates with more than 7,500 global team members who collaborate with customers across more than 30 market segments in over 140 countries to develop highly specified solutions. Following these announcements, the company's shares moved -0.73%, and are now trading at a price of $58.57. If you want to know more, read the company's complete 8-K report here.
